Brief: Nextcell Pharma Q2 Oper Loss Widens To SEK 11.4 Mln
27/04/2023 06:45
April 27 (Reuters) - NextCell Pharma AB NXTCL.ST :
* Q2 OPERATING INCOME AMOUNTED TO 2,734 (1,840) TSEK, OF
WHICH
CELLAVIVA COUNTED FOR 2,106 (1,279) TSEK
* Q2 OPERATING RESULT AMOUNTED TO -11,408 (-10,212) TSEK.
Source text for Eikon: ID:nWkr9DSKv2
Further company coverage: NXTCL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on NextCell Pharma AB
See all newsBrief: NextCell Pharma Q1 Operating Income At SEK 2.8 Million
Brief: Nextcell Pharma Q4 Operating Income SEK 1.8 Mln
Brief: Nextcell Pharma Says ProTrans Data Show Insulin Production Preservation
Brief: NextCell Board Proposes Directed Issue Of 15,000,000 Shares
Brief: Nextcell Decides To Propose Directed Share Issue Of SEK 15 Mln